不同分子亚型乳腺癌临床特征及治疗策略研究进展
被引量:1
摘要
乳腺癌是女性发病率最高的恶性肿瘤,是严重影响女性身心健康及生命安全的重要疾病之一。本文对上述4种乳腺癌亚型的生物学特性,治疗方法及预后进行分析与比较。
出处
《牡丹江医学院学报》
2013年第2期76-78,共3页
Journal of Mudanjiang Medical University
基金
泸州市科技计划资助项目[2012-S-36(4/14)]
参考文献18
-
1Garey LA, Perou CM,Livasy CA, et al. Race, breast cancer sub-types ,and survival in the Carolina BreastCancer Study [ J ] . JAMA,2006, 295(21) ,2492 -2502.
-
2Rakha EA,. El -Rehhim DA,Paish C,et cd. Basal phenotype identi-fies & poor prognostic subgroup of breast cancer of clinical importance[J].Eur J Cancer,2006,42(18) :3149 - 3156.
-
3Langerod A, 2iou H, Boi^an 0,et al. TP53 mutati<m status andgene expression prtrfiles are powerful prognostic markers of breastcanc?:[ J]. Breast Cancer Res,2007,9(3) :R30.
-
4Sortie T, Perou CM, Tlbshirani K, et al. Gene expiesaion patterns ofbreast carcinomas distinguish tumor subclasses with clinical implica-tions[J] . Proc Natl Acad Sci USA, 2001,98(19) :10869-10874.
-
5Hughes KS,Schnc^er LA,Beny D,? et al. Lumpectomy plus tamox-ifen widi or without iiradialion in women 70 years of age or older withearly breast cancer[J]. N Engl J Med, 2004 , 351(10):971 -977.
-
6Fyles AW,McCready DR, Manchul LA,et al. Tamoxifen with or with-out ineast inradiation in 'women 50 years td age or old扭 with eazlybreast cancer[J]. N En^ J Med,2004^ 351(10) :963 - 970.
-
7Fisher B,Coetantino JP,Wickerfiam DL,et al. Tamradfen for the pre-vention of breast cancer: current status of the National Surgical Adju-vant Breast and Bowel Project P - 1 study[ J]. J N^l Cancer Inst,2005 , 97(22):1652 - 62.
-
8Howell A,Cuzick J,Baum M, et al. Results of the ATAC (Arimidex,Tamoxifen, Alone or in Combination) trial after completion of 5 years. adjuvant treatment for breast cancer [ J ]. Lancet. 2005,365(9453):60-62.
-
9Grana G. Adjuvant aromatase inhibitor therapy for eazly breast canc-er: A review of the most recent data[ J]. J Surg Oncol ,2006,93(7 ):585 - 592.
-
10Breast International Group ( BIG) 1-98 Collaborative Group,ThUriimann B9 Keshaviah A, Coates AS, et al. A comparison ofletrozole and tamoxifen in postmenopausal women with early breastcancer[J]. N Engl J Med. 2005 , 353 ( 26) :2747 - 2757.
二级参考文献17
-
1PEROU C M,SORLIE T,EISEN M B,et al. Molecular portraits of human breast tumours [J]. Nature,2000,406 (6797) : 747 - 752.
-
2GAREY L A,PEROU C M, LIVASY C A,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA,2006,295(21 ) :2492 - 2502.
-
3SORLIE T,PEROU C M,TIBSHIANI R,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [ J ]. Proc Natl Acad Sci USA ,2001,98(19) : 10869 - 10874.
-
4RAKHA E A, EI-REHIM D A, PAISH C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance [ J ]. Cancer,2006,42: 3149 - 3156.
-
5LANGEROD A,ZHOU H,BORGAN O,et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer [J]. Breast Cancer Res, 2007,9:R30.
-
6CLEATOR S,HELLER W,COOMBES RC. Triple-negative breast cancer:therapeutic options [J]. Lancet Oncol, 2007,8(3 ) : 235 - 244.
-
7ONITILO A A, ENGEL J M, GREENLEE R T, et al. Breast cancer subtypes based on ER/PR and Her2 expression:comparison of clinicopathologic features and survival [J]. Clin Med Res,2009,7( 1-2):4 - 13.
-
8JAHANZEB M. Adjuvant/rastuzumab therapy for HER2- positive breast cancer [J]. Clin Breast Cancer,2008,8 (4) :324 - 333.
-
9LUND M J, BUTLER E N,BUMPERS H L,et al. High prevalence of triple-negative tumors in an urban cancer center[ J ]. Cancer, 2008,113 ( 3 ) : 608 - 615.
-
10GERSON R,ALBAN F,VILLALOBOS A,et al. Recurrence and survival rates among early breast cancer cases with triple-negative immunophenotype [J]. Gac Med Mex, 2008,144( 1 ):27 - 34.
共引文献4
-
1方琦,王旭芬.乳腺癌改良根治术后其分子亚型年复发风险分析[J].中国实用外科杂志,2012,32(11):938-941. 被引量:1
-
2陈飞宇,唐利立,肖志.中国湖南2324例乳腺癌临床特征及分子亚型分析[J].中国普通外科杂志,2013,22(11):1403-1409. 被引量:9
-
3刘明阁,冯稳,宋魏,孙淼淼,于庆凯.可手术的不同分子亚型乳腺癌的临床特征和生存研究[J].中国卫生标准管理,2016,7(14):30-31. 被引量:1
-
4陈显文,罗爱华,曾洲红,朱秀梅.改良根治术后的乳腺癌免疫组化3种分子亚型的预后特性研究[J].数理医药学杂志,2021,34(5):636-639.
同被引文献11
-
1东方,杨子银,何普明,林智.普洱茶抗氧化活性成分的LC-MS分析[J].中国食品学报,2008,8(2):133-141. 被引量:12
-
2顾睿,李瑞明,张兰兰,周水平,梁敬钰.普洱茶化学成分及药理研究进展[J].天津药学,2011,23(1):47-51. 被引量:12
-
3赵航,盛婧雪,李洪广,徐扬,赵璐,盛军,施维.普洱茶提取物对宫颈癌HeLa细胞的诱导凋亡作用[J].中国生物制品学杂志,2011,24(2):137-140. 被引量:6
-
4王烈,黎成金.乳腺癌治疗方法的变迁[J].中国临床医生杂志,2011,39(7):12-14. 被引量:9
-
5顾小盼,潘勃,吴臻,赵云芳,屠鹏飞,郑姣.普洱茶药理作用研究进展[J].中国中药杂志,2017,42(11):2038-2041. 被引量:10
-
6顾小盼,吴臻,靳凤玉,潘勃,赵云芳,李军,郑姣,屠鹏飞.普洱茶素Ⅰ改善糖脂代谢紊乱的药效评价及作用机制研究[J].中国中药杂志,2018,43(11):2339-2344. 被引量:7
-
7孟宪钰,付亚轩,李明超,徐天瑞,郝倩.普洱熟茶化学成分研究进展[J].食品与发酵工业,2019,45(12):285-290. 被引量:18
-
8Yixiao Feng,Mia Spezia,Shifeng Huang,Chengfu Yuan,Zongyue Zeng,Linghuan Zhang,Xiaojuan Ji,Wei Liu,Bo Huang,Wenping Luo,Bo Liu,Yan Lei,Scott Du,Akhila Vuppalapati,Hue H.Luu,Rex C.Haydon,Tong-Chuan He,Guosheng Ren.Breast cancer development and progression:Risk factors,cancer stem cells,signaling pathways,genomics,and molecular pathogenesis[J].Genes & Diseases,2018,5(2):77-106. 被引量:28
-
9陈安莉,沈浩元,王舒.三阴性乳腺癌新辅助治疗的临床研究进展[J].现代肿瘤医学,2023,31(3):566-571. 被引量:8
-
10王鑫玉,赵一慕,高云,阴紫钰,王凌潇,马家乐,赵云芳,郑姣,李军.普洱茶素Ⅱ改善高脂血症ApoE-/-小鼠动脉粥样硬化作用机制研究[J].中草药,2023,54(4):1157-1163. 被引量:3
-
1陆军,祝进,徐礼锋,白永凤,李向阳.社区与医院获得性耐甲氧西林金黄色葡萄球菌耐药性分析与比较[J].中国卫生检验杂志,2012,22(2):380-382. 被引量:14
-
2姜岱山,卞婷婷,李山峰,周忠霞,奚培培,蒋伟.成人肺炎支原体感染患者的临床特征及治疗研究[J].中国全科医学,2016,19(B12):200-202. 被引量:1
-
3熊夏思,陈士岭.体外受精胚胎移植周期中获卵数少于十个的临床结局分析[J].广东医学,2008,29(6):947-948. 被引量:3
-
4杨平,陈晓云.新生儿表皮葡萄球菌败血症48例临床分析[J].中国乡村医药,2004,11(5):34-34.
-
5徐岚,胡炯,吴文,唐暐,闫骅,赵维莅,高晓东,沈志祥.造血干细胞移植后早期侵袭性真菌感染的临床分析[J].诊断学理论与实践,2007,6(4):358-361. 被引量:3
-
6任长娟.小儿肺炎支原体感染98例临床分析[J].中国医药指南,2012,10(9):427-428. 被引量:2
-
7郑立军.消化性溃疡患者的临床诊治分析[J].中国保健营养(临床医学学刊),2010,19(6):141-142.
-
8田小兰,彭清林,舒晓明,卢昕,王国春.多发性肌炎/皮肌炎患者血清中可溶性人类白细胞抗原-G表达水平的研究[J].中华风湿病学杂志,2013,17(5):313-317. 被引量:2
-
9葛哲,殷水泽,肖安,杨建军.5例埃博拉病毒病病例临床特征及治疗转归分析[J].西南国防医药,2015,25(9):972-974. 被引量:1
-
10刘义,赵艳杰,张均田.人参和西洋参对小鼠脾淋巴细胞内游离钙浓度的作用分析与比较[J].中国药理学通报,1998,14(3):286-287. 被引量:9